ArticleNPJ Parkinson's disease2026
Neuroimaging evidence of microstructural alteration in Parkinson's disease with subjective cognitive decline.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Subjective cognitive decline (SCD) may represent a special cognitive stage distinct from mild cognitive impairment (MCI) in Parkinson's disease (PD), but its microstructural correlates are underexplored. We aimed to investigate microstructural alterations in PD-SCD compared to PD with normal cognition (PD-NC) and PD-MCI, and to explore their association with cognitive status. 68 PD patients (PD-NC: n = 23; PD-SCD: n = 20; PD-MCI: n = 25) and 27 healthy controls (HC) underwent multimodal MRI. Analyses included tract-based spatial statistics (TBSS), calculation of the peak width of skeletonized mean diffusivity (PSMD), and hippocampal subfield segmentation. PSMD showed significant differences across subgroups and negatively correlated with MoCA scores, suggesting its utility as a metric that differentiated cognitive stage. TBSS revealed reduced fractional anisotropy (FA) in multiple tracts in PD-MCI, while PD-SCD exhibited reduced FA only in FMajor relative to HC. Hippocampal subfield segmentation revealed atrophy in subregions such as CA1 and HATA in PD-SCD and PD-MCI compared to PD-NC. This study provides evidence that microstructural alterations are already detectable at the PD-SCD stage. PSMD emerges as a sensitive cross-sectional biomarker of PD cognitive staging. These findings highlight the potential role of white‑matter changes in PD‑related cognitive complaints.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.